Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Geovax Labs (GOVX)

Geovax Labs (GOVX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 7,352
  • Shares Outstanding, K 2,308
  • Annual Sales, $ 0 K
  • Annual Income, $ -25,970 K
  • 60-Month Beta 2.77
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 150.98
Trade GOVX with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate -3.04
  • Number of Estimates 1
  • High Estimate -3.04
  • Low Estimate -3.04
  • Prior Year -3.30
  • Growth Rate Est. (year over year) +7.88%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.09 +238.96%
on 06/18/24
4.90 -24.59%
on 06/27/24
+1.87 (+103.02%)
since 05/31/24
3-Month
1.09 +238.96%
on 06/18/24
4.90 -24.59%
on 06/27/24
+1.73 (+88.52%)
since 04/01/24
52-Week
1.09 +238.96%
on 06/18/24
10.24 -63.92%
on 07/24/23
-4.56 (-55.21%)
since 06/30/23

Most Recent Stories

More News
Pancreatic Cancer Market Is Projecting to Expand As NCI-Funded Research Expects to Empower Market Growth

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:GOVX),(NYSE:GSK),(NASDAQ:AZN),(NYSE:MRK) EQNX::TICKER_END

ONCY : 0.9999 (+1.00%)
ONC.TO : 1.35 (-2.17%)
GOVX : 3.45 (+8.49%)
GSK : 38.93 (+1.12%)
AZN : 78.63 (+0.82%)
MRK : 128.44 (+3.75%)
Pancreatic Cancer Market Is Projecting to Expand As NCI-Funded Research Expects to Empower Market Growth

ONCY : 0.9999 (+1.00%)
ONC.TO : 1.35 (-2.17%)
GOVX : 3.45 (+8.49%)
GSK : 38.93 (+1.12%)
AZN : 78.63 (+0.82%)
MRK : 128.44 (+3.75%)
GeoVax Reports 2022 Second Quarter Financial Results and Provides Corporate Update

Advancing Phase 2 Clinical Trials for COVID-19 and Immuno-Oncology Evaluation of Company’s Vaccine Platform Against Monkeypox Underway ATLANTA, GA,...

GOVX : 3.45 (+8.49%)
GOVXW : 0.1400 (+3.70%)
GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate Against Sudan Ebolavirus Showing 100% Protection With a Single Immunization

ATLANTA, GA, July 28, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing human vaccines and...

GOVXW : 0.1400 (+3.70%)
GOVX : 3.45 (+8.49%)
GeoVax to Report Second Quarter 2022 Financial Results on Wednesday, August 3, 2022 and Provide Corporate Update

Conference Call to be Held Wednesday, August 3, at 4:30 p.m. Eastern Time ATLANTA, GA, July 26, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs,...

GOVXW : 0.1400 (+3.70%)
GOVX : 3.45 (+8.49%)
GeoVax to Present at BIO International Convention 2022

Company to Provide Updates on Phase 2 Clinical Trials for COVID-19 Vaccine and Immuno-oncology/Gedeptin® Atlanta, GA, June 07, 2022 (GLOBE NEWSWIRE)...

GOVXW : 0.1400 (+3.70%)
GOVX : 3.45 (+8.49%)
GeoVax Announces $20 Million Registered Direct and PIPE Offerings Priced at a Premium to Market Under Nasdaq Rules

Atlanta, GA, May 25, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing...

GOVXW : 0.1400 (+3.70%)
GOVX : 3.45 (+8.49%)
GeoVax Receives Notice of Allowance for Cancer Vaccine Patent in China

Atlanta, GA, May 24, 2022 (GLOBE NEWSWIRE) -- IND-Enabling Studies Underway in the United States for MVA-VLP-MUC1 Vaccine Candidate via NewMediaWire...

GOVXW : 0.1400 (+3.70%)
GOVX : 3.45 (+8.49%)
GeoVax Announces Upcoming Presentations at Scientific Conferences

ATLANTA, GA, May 04, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire –GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing human vaccines and...

GOVXW : 0.1400 (+3.70%)
GOVX : 3.45 (+8.49%)
GeoVax Announces Issuance of Malaria Vaccine Patent

GeoVax’s Unique Multi-Antigenic Vaccine Approach Designed to Provide Stronger, Broader Protection Against Malaria Atlanta, GA, April 26, 2022 (GLOBE...

GOVXW : 0.1400 (+3.70%)
GOVX : 3.45 (+8.49%)

Business Summary

GeoVax Labs Inc. is a clinical-stage biotechnology company. It engages in developing human vaccines against infectious diseases and cancer using a novel patented Modified Vaccinia Ankara-Virus Like Particle based vaccine platform. GeoVax Labs Inc. is based in ATLANTA, GA.

See More

Key Turning Points

3rd Resistance Point 5.68
2nd Resistance Point 5.11
1st Resistance Point 4.15
Last Price 3.57
1st Support Level 2.62
2nd Support Level 2.05
3rd Support Level 1.09

See More

52-Week High 10.24
Fibonacci 61.8% 6.75
Fibonacci 50% 5.67
Fibonacci 38.2% 4.59
Last Price 3.57
52-Week Low 1.09

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar